Day: November 12, 2019

Partnership brings tennis to visually impaired players in LICProvides adaptive equipment such as sound tennis balls for participantsNEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) — BNP Paribas, one of the leading sponsors of tennis globally, further fulfilled its commitment to make tennis available to all players, regardless of income or physical limitations, by partnering with Court 16 and Helen Keller Services for the Blind to launch the Sound of Tennis program today in Long Island City. The program will offer visually impaired adults in the NYC area the opportunity to play tennis using sound adapted foam tennis balls on a modified court.The effort was kicked off today at a ceremony at Court 16’s Long Island City location, which included visually impaired tennis players. Two-hour classes will be offered weekly at no charge to qualifying...

ATLANTA, Nov. 12, 2019 (GLOBE NEWSWIRE) —Named to Prestigious List for Fourth Consecutive YearRecognized as Transportation Industry LeaderScored #1 in the Transportation Categories for Communities, Customers and the EnvironmentUPS (NYSE: UPS) today announced it was named to Forbes and JUST Capital’s annual “JUST 100” list for the fourth consecutive year. The company was again recognized as the industry leader in the transportation sector. UPS also scored first in the transportation categories for community, customers and the environment.“It is rewarding to see UPS being acknowledged by two well-respected entities for its leadership efforts in social responsibility,” said Suzanne Lindsay-Walker, chief sustainability officer (CSO) and vice president of environmental affairs, UPS. “This prominent distinction demonstrates that UPS’s...

HALIFAX, Nova Scotia, Nov. 12, 2019 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce operating and financial results for the three and nine months ended September 30, 2019, and to provide an update on its recently announced financing led by the European Bank for Reconstruction and Development (“EBRD”). This release should be read in conjunction with the Company’s Q3-2019 Financial Statements, MD&A and Annual Information Form, available on the Company’s website or SEDAR.Quotes from the Company:“We continue to meet significant milestones with a strategic financing led by the EBRD, delivery of our Pre-Feasibility Study, and continued exploration success,” said Peter Akerley, Erdene’s President and CEO. “Our Q3 successes bring us...

BEIJING, Nov. 12, 2019 (GLOBE NEWSWIRE) — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (OTCMKTS: CCIHY), a leading total solutions provider of Internet content and application delivery services in China, today announced that ChinaCache Network Technology (Beijing) Co., Limited (“ChinaCache Network”) has been imposed a fine of RMB 900,000 by Tangyin County People’s Court of Henan Province due to ChinaCache Network’s company bribery. This case has been completed and ChinaCache Network has performed the judgement.About ChinaCache International Holdings Ltd.ChinaCache International Holdings Ltd. is a leading total solutions provider of Internet content and application delivery services in China. Through its distinctive 3-tier Internet ecosystem, ChinaCache also offers Internet data center...

Managing Director of TS Capital UK, Sal J Shah, appointed by leading provider of innovative blockchain business solutions, Appliqate Inc, as a member of the advisory boardNew York, Nov. 12, 2019 (GLOBE NEWSWIRE) — Appliqate Inc. (“Appliqate”) (OTC: APQT) Sal J Shah is an experienced business executive and is currently the Chief Executive Office of TS Capital Partners Ltd. Sal was recently appointed to join the advisory board of Appliqate Inc, a technology development firm providing clients with easy access to innovative blockchain business solutions. The move is in line with the company’s goal of providing the best possible solutions to their clients across aboard, leveraging Sal’s expertise to better serve their clients.As a strategic leader and executive with extensive international experience in varied roles across different...

ATLANTA, Nov. 12, 2019 (GLOBE NEWSWIRE) — Five9, Inc. (FIVN), the leading provider of the intelligent cloud contact center, recently announced that Jacada was awarded the ISV Partner of the Year for 2019. The award was presented by Dan Burkland, Five9 President, to Jacada at the inaugural Five9 Partner Awards at their annual CX Summit. These awards recognize standout ecosystem partners that are committed to delivering extraordinary customer experiences and consistent results to their mutual customers. Jacada’s Customer Service RPA platform delivers end-to-end customer service automation to Five9 clients by providing seamless intelligent automation solutions to enhance the customer experience (CX) and employee experience (EX).Over the last 18 months, the Five9 and Jacada partnership has garnered praise inside and out of the organizations....

On 12 November 2019 primary insider Ole Gunnar Jakobsen, Plant Director, Sarpsborg Site, exercised 25,000 stock options at a strike price of NOK 42.24 per share.In a related transaction, Borregaard repurchased 25,000 own shares from Ole Gunnar Jakobsen at an average price of NOK 91.95 per share. The repurchase is conducted in accordance with a proxy given at the Ordinary General Meeting held on 11 April 2019.After the transaction, Ole Gunnar Jakobsen owns 30,819 shares and has 50,000 stock options in Borregaard.The total number of outstanding Borregaard stock options following this transaction is 1,401,000. Borregaard owns 369,384 treasury shares, representing 0.37% of the total number of shares outstanding.Borregaard ASASarpsborg, 12 November 2019Contact:Lotte Kvinlaug, Investor Relations Officer, + 47 922 86 909This information is subject...

DALLAS, Nov. 12, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed a second party has approached the company to express interest in acquiring KALY’s U.S. Patented Cannabis Extraction Process and related biopharmaceutical technology valued at $50 million.  KALY recently announced entering into discussions with a first investor to explore a possible sale of KALY’s cannabis biopharmaceutical technology.  The first investor valued the technology at $50 million.  KALY management considers the valuation consistent with Goldman Small Cap Research’s recent valuation, but management maintains a position that the valuation still does not reflect the full potential of its intellectual property.  The second party expressing interest has not yet communicated...

Press releaseHørsholm, Denmark, 12 November 2019 – Oncology Venture A/S (“OV” or the “Company”) extends the subscription period until 21 November 2019. The reason for the extension is that new and important information has been made public today, 12 November 2019, and the Company therefore wishes to provide the shareholders with enough time to review and evaluate such information.The board’s resolution to extend the period for subscription and payment of Units, with or without pre-emption rights, may thereby be made from 31 October until 21 November 2019.Complete information about the rights issue is included in the prospectus available on the Company’s website, www.oncologyventure.com, and on Hagberg & Aneborn Fondkommission’s website, www.hagberganeborn.se.For further information, please contact:Henrik Moltke, CFOE-mail: hm@oncologyventure.comTelephone...

  Company NewsHørsholm, Denmark (12 November 2019) – Oncology Venture A/S (“OV” or the Company) today announced an update on the progress of its ongoing U.S. Phase 2 clinical trial for its PARP inhibitor, 2X-121, for the treatment of ovarian cancer, sited at the Dana-Farber Cancer Institute (Boston, MA, U.S.A.).The cancer drug 2X-121 (formerly E7449) is a small molecule, targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells, which was originally developed by the pharmaceutical company Eisai.  The company has recently announced this drug as one of its top priority programs. 2X-121 is currently being evaluated for the treatment of advanced ovarian cancer in a DRP®-guided Phase 2 clinical trial at the Dana-Farber Cancer Institute (Boston, MA U.S.A.).  Thus far, 8 patients are enrolled...